title: Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial.
abstract: BACKGROUND
  The social stigma and chronicity of psoriasis significantly affect health-related quality of life (HRQoL).
  
  
  OBJECTIVE
  We examined the effect of three regimens of secukinumab on HRQoL in moderate to severe psoriasis patients.
  
  
  METHODS
  Twelve-week data from a phase II, randomized, double-blind, placebo-controlled, regimen-finding study evaluated HRQoL, measured by the Dermatology Life Quality Index (DLQI). Secukinumab or placebo was administered subcutaneously in three treatment regimens: single (baseline only), monthly (baseline, weeks 4, 8) and early (baseline, weeks 1, 2, 4). Differences among regimens were assessed with logistic regression models and Fisher's exact test.
  
  
  RESULTS
  Patients (n = 404) were randomized to single (baseline) treatment regimen, n = 66; monthly, (baseline, weeks 4 and 8), n = 138; early, (baseline, weeks 1, 2, 4), n = 133; and placebo, n = 67. DLQI response was significantly higher in early, monthly and single regimens than in placebo regimen (40.8%, 33.6% and 13.1% vs. 1.6%, respectively; P < 0.001 for all).
  
  
  CONCLUSIONS
  Moderate to severe psoriasis patients receiving monthly and early treatment with secukinumab demonstrated improved HRQoL compared with placebo.
authors.affiliation: Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Augustin
authors.affiliation: RTI Health Solutions, Didsbury, UK.
authors.forename: S
authors.initials: S
authors.lastname: Abeysinghe
authors.affiliation: Novartis Pharmaceuticals Corp., East Hanover, NJ, USA.
authors.forename: U
authors.initials: U
authors.lastname: Mallya
authors.affiliation: Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Qureshi
authors.affiliation: CROS NT Ltd., Milton Keynes, UK.
authors.forename: N
authors.initials: N
authors.lastname: Roskell
authors.affiliation: RTI Health Solutions, Didsbury, UK.
authors.forename: D
authors.initials: D
authors.lastname: McBride
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Papavassillis
authors.affiliation: Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Gelfand
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010919:Placebos; C555450:secukinumab